Publication:
The continuous heart failure spectrum: Moving beyond an ejection fraction classification

dc.contributor.authorTriposkiadis, Filippos (55399494500)
dc.contributor.authorButler, Javed (57203521637)
dc.contributor.authorAbboud, Francois M. (7102796868)
dc.contributor.authorArmstrong, Paul W. (35380325200)
dc.contributor.authorAdamopoulos, Stamatis (55399885400)
dc.contributor.authorAtherton, John J. (57202810067)
dc.contributor.authorBacks, Johannes (6506659543)
dc.contributor.authorBauersachs, Johann (7004626054)
dc.contributor.authorBurkhoff, Daniel (7006163840)
dc.contributor.authorBonow, Robert O. (7102250069)
dc.contributor.authorChopra, Vijay K. (57213319493)
dc.contributor.authorDe Boer, Rudolf A. (8572907800)
dc.contributor.authorDe Windt, Leon (7004313195)
dc.contributor.authorHamdani, Nazha (23094208600)
dc.contributor.authorHasenfuss, Gerd (26643367300)
dc.contributor.authorHeymans, Stephane (6603326423)
dc.contributor.authorHulot, Jean-Sébastien (6603026259)
dc.contributor.authorKonstam, Marvin (55628580428)
dc.contributor.authorLee, Richard T. (7408204096)
dc.contributor.authorLinke, Wolfgang A. (7004812764)
dc.date.accessioned2025-06-12T15:08:41Z
dc.date.available2025-06-12T15:08:41Z
dc.date.issued2019
dc.description.abstractRandomized clinical trials initially used heart failure (HF) patients with low left ventricular ejection fraction (LVEF) to select study populations with high risk to enhance statistical power. However, this use of LVEF in clinical trials has led to oversimplification of the scientific view of a complex syndrome. Descriptive terms such as ‘HFrEF’ (HF with reduced LVEF), ‘HFpEF’ (HF with preserved LVEF), and more recently ‘HFmrEF’ (HF with mid-range LVEF), assigned on arbitrary LVEF cut-off points, have gradually arisen as separate diseases, implying distinct pathophysiologies. In this article, based on pathophysiological reasoning, we challenge the paradigm of classifying HF according to LVEF. Instead, we propose that HF is a heterogeneous syndrome in which disease progression is associated with a dynamic evolution of functional and structural changes leading to unique disease trajectories creating a spectrum of phenotypes with overlapping and distinct characteristics. Moreover, we argue that by recognizing the spectral nature of the disease a novel stratification will arise from new technologies and scientific insights that will shape the design of future trials based on deeper understanding beyond the LVEF construct alone. © The Author(s) 2019.
dc.identifier.urihttps://doi.org/10.1093/eurheartj/ehz158
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85068687380&doi=10.1093%2feurheartj%2fehz158&partnerID=40&md5=8b51e9a04c1c4b44ac5447a99d7e7b08
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/5513
dc.subjectEjection fraction
dc.subjectEndothelium
dc.subjectHeart failure
dc.subjectPathophysiology
dc.titleThe continuous heart failure spectrum: Moving beyond an ejection fraction classification
dspace.entity.typePublication

Files